Affordable measles and rubella vaccines using NevoLine manufacturing platform

14 Jun 2019

Univercells' propriety bioproduction platform has already proven success.

Univercells has been awarded a $14.3 million grant by the Bill & Melinda Gates Foundation to increase the availability of measles and rubella (M&R) vaccines in low- and middle-income countries (LMICs). Univercells will adapt the process design of its proprietary NevoLine platform to deliver affordable M&R vaccines. This novel manufacturing platform has already proven success with its initial application for Sabin inactivated polio vaccine (sIPV), supported by a $12 million Grand Challenges grant awarded by the Bill & Melinda Gates Foundation.

Affordable measles and rubella vaccines using NevoLine manufacturing platform

Viral infectious diseases, such as measles and rubella, still represent a significant global health burden despite preventability via vaccination. Effective vaccination programs in LMICs are impaired by a substantial gap of affordable vaccines. Conventional vaccine manufacturing requires high capital and operating costs and does not provide a sustainable or cost-effective solution for the future. Univercells will leverage its NevoLine bioproduction platform to sustainably supply measles and rubella vaccines at an affordable cost by minimizing equipment and facility-related capital investment together with lower operating costs.

Under the terms of the agreement, Univercells will develop a NevoLine platform for the measles and rubella processes and initiate clinical validation. As part of this project, Univercells’ partner Batavia Biosciences will adapt its highly intensified production process to the M&R vaccines and manufacture GMP material. Univercells will also explore utilizing novel vaccine delivery technologies under evaluation by the foundation. Combining innovations could further reduce costs, facilitate the execution of immunization campaigns and improve accessibility of critical vaccines.

“We are very honored to receive this grant and work once again with the Bill & Melinda Gates Foundation to increase affordability of the M&R vaccine, another critical vaccine especially in view of the recent outbreaks worldwide,” said Hugues Bultot, CEO and co-founder of Univercells. “We are dedicated to delivering a portfolio of viral vaccines such as inactivated polio, measles and rubella and other undersupplied vaccines to further increase the availability of these life - saving products.”

José Castillo, CTO and co-founder of Univercells added: “This second project with the foundation confirms the trust built upon our breakthrough technology. It enables Univercells to demonstrate the potential of our NevoLine manufacturing platform to be a game - changer for global health.”

Read More

Related news

iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more 
PCI Pharma Services completes biotech Center of Excellence

PCI Pharma Services completes biotech Center of Excellence

29 Jun 2020

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

Read more 
DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

29 Jun 2020

SeaGel offers drug and dietary supplement manufacturers an animal-free and sustainable alternative to traditional soft capsules.

Read more 
Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
TraceLink announces results from FDA DSCSA Pilot Program

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

Read more